Shuhui Li, Yuansheng Liu, Xiaojun Sui, Yuzhen Zhuo, He Siqi, Zhang Sijia, Zhang Hui, Li Dihua, Zhang Dapeng, Yang Lei
{"title":"Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer.","authors":"Shuhui Li, Yuansheng Liu, Xiaojun Sui, Yuzhen Zhuo, He Siqi, Zhang Sijia, Zhang Hui, Li Dihua, Zhang Dapeng, Yang Lei","doi":"10.1080/17435889.2024.2382076","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the anti-pancreatic cancer effect of novel Tubeimoside I multifunctional liposomes combined with gemcitabine.<b>Methods:</b> Liposomes were prepared through the thin film hydration method, with evaluations conducted on parameters including encapsulation efficiency (EE%), particle size, polydispersity index (PDI), zeta potential (ZP), storage stability, and release over a 7-day period. The cellular uptake rate, therapeutic efficacy <i>in vitro</i> and <i>in vivo</i> and the role of immune microenvironment modulation were evaluated.<b>Results:</b> The novel Tubeimoside I multifunctional liposomal exhibited good stability, significant anti-cancer activity, and immune microenvironment remodeling effects. Furthermore, it showed a safety profile.<b>Conclusion:</b> This study underscores the potential of Novel Tubeimoside I multifunctional liposomal as a promising treatment option for pancreatic cancer.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2382076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To evaluate the anti-pancreatic cancer effect of novel Tubeimoside I multifunctional liposomes combined with gemcitabine.Methods: Liposomes were prepared through the thin film hydration method, with evaluations conducted on parameters including encapsulation efficiency (EE%), particle size, polydispersity index (PDI), zeta potential (ZP), storage stability, and release over a 7-day period. The cellular uptake rate, therapeutic efficacy in vitro and in vivo and the role of immune microenvironment modulation were evaluated.Results: The novel Tubeimoside I multifunctional liposomal exhibited good stability, significant anti-cancer activity, and immune microenvironment remodeling effects. Furthermore, it showed a safety profile.Conclusion: This study underscores the potential of Novel Tubeimoside I multifunctional liposomal as a promising treatment option for pancreatic cancer.
目的：评估新型 Tubeimoside I 多功能脂质体联合吉西他滨的抗胰腺癌效果：方法：采用薄膜水合法制备脂质体，并对其封装效率（EE%）、粒度、多分散指数（PDI）、ZP、储存稳定性和 7 天释放等参数进行评估。对细胞摄取率、体外和体内疗效以及免疫微环境调节作用进行了评估：结果：新型 Tubeimoside I 多功能脂质体具有良好的稳定性、显著的抗癌活性和免疫微环境重塑作用。此外，它还显示出良好的安全性：本研究强调了新型 Tubeimoside I 多功能脂质体作为胰腺癌治疗选择的潜力。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
